Nasdaq Grants Delisting Extension to March 27, 2026; Reverse Split Possible
RVPH sits 34% above its 52-week low of $0.25 on light trading volume (0.3× avg).
Summary
The company received an extension from Nasdaq until March 27, 2026, to regain compliance with the minimum bid price requirement, with a reverse stock split being a potential solution.
Key Events · Corporate Governance and Compliance · RVPH
-
Nasdaq Grants Delisting Exception
The Nasdaq Hearings Panel granted an exception allowing the company until March 27, 2026, to demonstrate compliance with the $1.00 minimum bid price requirement.
-
Ongoing Delisting Risk
This extension follows a previous delisting notice from Nasdaq on November 11, 2025, due to the company's failure to meet the bid price requirement by November 10, 2025.
-
Potential Reverse Stock Split
The company stated its intention to take definitive steps to regain compliance, including implementing a reverse stock split if necessary, which could negatively affect the stock price and liquidity.
Analysis · RVPH · Life Sciences
Reviva Pharmaceuticals Holdings, Inc. has secured a temporary reprieve from Nasdaq delisting, receiving an extension until March 27, 2026, to regain compliance with the $1.00 minimum bid price requirement. While this averts immediate delisting, the company remains in a precarious position, trading significantly below the required threshold. The stated intention to consider a reverse stock split, if necessary, highlights the ongoing challenge and potential for further share price volatility and liquidity concerns. Investors should monitor the company's progress towards compliance and any announcements regarding a reverse stock split, as failure to meet the deadline could lead to delisting and severely impact the stock's liquidity and valuation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVPH was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $0.25 to $2.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.